The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination
Open accessAbstract
Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. In this observational study we show that, in healthy adult individuals ( n = 96), the heterologous vaccine regimen induced spike-specific IgG, neutralizing antibodies and spike-specific CD4 T cells, the levels of which which were significantly higher than after homologous vector vaccine boost ( n = 55) and higher or comparable in magnitude to homologous mRNA vaccine regimens ( n = 62). Moreover, spike-specific CD8 T cell levels after heterologous vaccination were significantly higher than after both homologous regimens. Spike-specific T cells were predominantly polyfunctional with largely overlapping cytokine-producing phenotypes in all three regimens. Recipients of both the homologous vector regimen and the heterologous vector/mRNA combination reported greater reactogenicity following the priming vector vaccination, whereas heterologous boosting was well tolerated and comparable to homologous mRNA boosting. Taken together, heterologous vector/mRNA boosting induces strong humoral and cellular immune responses with acceptable reactogenicity profiles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R
Chen, H., & Boutros, P. C. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-35 · Cited by 3,131
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Cited by
Homologous and Heterologous Covid-19 Booster Vaccinations
Atmar, R. L., Lyke, K. E., Deming, M. E., Jackson, L. A., Branche, A. R., El Sahly, H. M., Rostad, C. A., Martin, J. M., Johnston, C., Rupp, R. E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116414 · Cited by 654
The use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines
Sette, A., & Crotty, S. (2022) · Immunological Reviews · doi:10.1111/imr.13089 · Cited by 269
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
Hall, V. G., Ferreira, V. H., Wood, H., Ierullo, M., Majchrzak-Kita, B., Manguiat, K., Robinson, A., Kulasingam, V., Humar, A., & Kumar, D. (2022) · Nature Immunology · doi:10.1038/s41590-021-01126-6 · Cited by 114
Metadata
- Authors
- Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Schneitler, S., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M.
- Venue
- Nature Medicine
- Published
- 2021-07-26
- Volume
- 27
- Issue
- 9
- Pages
- 1530-1535
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W3186217635
- Cited by
- 340
- References
- 20
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. https://app.cochat.ai/papers/10.1038/s41591-021-01464-w
- The paper
- Schmidt, T., Klemis, V., Schub, D., Mihm, J., Hielscher, F., Marx, S., Abu-Omar, A., Ziegler, L., Guckelmus, C., Urschel, R., Schneitler, S., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M. (2021). Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nature Medicine. https://doi.org/10.1038/s41591-021-01464-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.